Dynamic and Isometric Strength Training in Older Adults With Hypertension (Dynamic and Is)

April 27, 2026 updated by: Raphael Mendes Ritti Dias

Effects of Dynamic Strength Training and Isometric Strength Training on Cardiovascular Health Indicators, Mental Health, and Neuromuscular Fitness in Older Adults With Hypertension: A Feasibility Study

This feasibility study aims to evaluate the effects of dynamic strength training and isometric strength training on cardiovascular health indicators, mental health, and neuromuscular fitness in older adults with hypertension. Participants will be randomly assigned to one of the two training modalities and will complete supervised exercise sessions throughout the intervention period. The study will provide preliminary evidence regarding the safety, acceptability, and potential impact of each training modality on health outcomes in this population.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Brazil
    • São Paulo
      • São Paulo, São Paulo, Brazil, 01525-000
        • Recruiting
        • UNINOVE

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion criteria:

  • Diagnosis of arterial hypertension and currently taking antihypertensive medication
  • Age 60 years or older
  • Resting blood pressure below 160/95 mmHg
  • No high cardiovascular risk according to the American College of Sports Medicine criteria (for participants with type 2 diabetes, glycemic control with fasting glucose <100 mg/dL and postprandial glucose <140 mg/dL)
  • Not participating in a structured exercise program for more than three months
  • No cognitive or functional limitations that prevent participation in the exercise program

Exclusion Criteria

  • Presence of acute illnesses, such as influenza, sinusitis, gastroenteritis, urinary tract infection, fever, inflammatory processes, or any clinical condition requiring rest or that may compromise safety during assessments or training.
  • Decompensated clinical conditions, including: Blood pressure spikes, Chest pain, Uncontrolled arrhythmias, Shortness of breath at rest, Asthma exacerbations, Decompensated diabetes mellitus, characterized by Persistently elevated blood glucose levels (fasting glucose > 180 mg/dL or postprandial glucose > 250 mg/dL)
  • Irregular use of medication
  • Any unstable clinical condition or condition that represents additional risk for the practice of physical exercise.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Dynamic Strength Training
The subjects randomized to this group will perform two supervised dynamic strength training sessions per week for 6 weeks, each session lasting approximately 30 minutes.
Behavioral: Dynamic Strength Training
The experimental group will perform dynamic strength exercises targeting major muscle groups, progressing in intensity and volume over the 6 weeks. Exercises include 8 major muscle group movements, initially 2 sets of 15 repetitions (Borg 4-6), progressing to 3 sets of 10 repetitions (Borg 5-7) from week 5. Participants will also be advised to perform non-supervised walking 3-5 times per week for ~30 minutes at moderate intensity.
Experimental: Isometric Strength Training
The subjects randomized to this group will perform two supervised isometric strength training sessions per week for 6 weeks, each session lasting approximately 30 minutes.
Behavioral: Isometric Strength Training
The experimental group will perform isometric strength exercises targeting major muscle groups, progressing in intensity and volume over the 6 weeks. Exercises include 8 major muscle group contractions, initially 2 sets of 60 seconds (Borg 4-6), progressing to 3 sets of 40 seconds (Borg 5-7) from week 5. Participants will also be advised to perform non-supervised walking 3-5 times per week for ~30 minutes at moderate intensity.
Other: Control
No supervised training will be provided. Participants in this group will not receive any exercise intervention during the 6-week study period, but they will be stimulated to be active.
Behavioral: No supervised intervention Control
This group serves as a control and will not perform any structured exercise program.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Recruitment rate
Time Frame: Baseline and 6 weeks
Proportion of enrolled participants relative to the total number of eligible individuals contacted. Reported as a percentage.
Baseline and 6 weeks
Adherence to training sessions
Time Frame: During 6 weeks
Percentage of completed training sessions relative to the total number of planned sessions over the 6-week intervention period.
During 6 weeks
Retention rate
Time Frame: During 6 weeks
Proportion of participants who complete the full 6-week intervention
During 6 weeks
Fidelity to exercise protocol
Time Frame: Duiring 6 weeks
Percentage of exercises performed according to the prescribed protocol parameters, including load, repetitions, and time under tension.
Duiring 6 weeks
Acceptability of the intervention
Time Frame: During 6 weeks
Acceptability assessed through a structured satisfaction questionnaire, scored from 0 to 10, administered at the end of the 6-week intervention
During 6 weeks
Occurrence of adverse events
Time Frame: During 6 weeks
Number of intervention-related adverse events, classified as mild, moderate, or severe
During 6 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change from baseline in Clinical resting blood pressure at 6 weeks
Time Frame: Baseline and 6 weeks
Systolic and diastolic blood pressure measured with automatic device (HEM-742, Omron Healthcare, Japan) in seated position, average of last two of three readings, in millimeters of mercury.
Baseline and 6 weeks
Change from baseline in Home blood pressure monitoring at 6 weeks
Time Frame: Baseline and 6 weeks
Seven-day home monitoring with automatic device (Omron Healthcare, Japan), two readings morning and evening in duplicate; average of valid readings, in millimeters of mercury
Baseline and 6 weeks
Change from baseline in Flow-mediated dilation at 6 weeks
Time Frame: Baseline and 6 weeks
Brachial and femoral artery vasodilation assessed by ultrasonography with spectral Doppler (Cannon Xario, Japan); calculated as percentage change from baseline
Baseline and 6 weeks
Change from baseline in Standard deviation of normal R-R intervals at 6 weeks
Time Frame: Baseline and 6 weeks
Standard deviation of normal R-R intervals will be assessed using the Polar V800 heart rate monitor (Polar Electro, Finland) and expressed in milliseconds (ms).
Baseline and 6 weeks
Change from baseline in Arterial stiffness at 6 weeks
Time Frame: Baseline and 6 weeks
Carotid-femoral pulse wave velocity measured by applanation tonometry (SphygmoCor, AtCor Medical, Australia), calculated as distance/time in meters per second
Baseline and 6 weeks
Change from baseline in Depressive symptoms at 6 weeks
Time Frame: Baseline and 6 weeks
Geriatric Depression Scale (GDS-15), 15 items, scored 0-15, higher score = worse symptoms
Baseline and 6 weeks
Change from baseline in Anxiety symptoms at 6 weeks
Time Frame: Baseline and 6 weeks
Generalized Anxiety Disorder questionnaire (GAD-7), 7 items, scored 0-21, higher score = worse symptoms
Baseline and 6 weeks
Change from baseline in Six-Minute Walk Test distance at 6 weeks
Time Frame: Baseline and 6 weeks
Distance walked in meters during the six-minute walk test performed in a 30-meter corridor.
Baseline and 6 weeks
Change from baseline in Root mean square of successive differences between R-R intervals at 6 weeks
Time Frame: Baseline to 6 weeks
Root mean square of successive differences between R-R intervals will be measured using the Polar V800 heart rate monitor (Polar Electro, Finland) and expressed in milliseconds (ms).
Baseline to 6 weeks
Change from baseline in Proportion of successive R-R intervals differing by more than 50 milliseconds at 6 weeks
Time Frame: Baseline to 6 weeks.
Proportion of successive R-R intervals differing by more than 50 milliseconds will be measured using the Polar V800 heart rate monitor (Polar Electro, Finland) and expressed in milliseconds (ms).
Baseline to 6 weeks.
Change from baseline in Low-frequency spectral power at 6 weeks
Time Frame: Baseline to 6 weeks.
Low-frequency spectral power will be assessed using the Polar V800 (Polar Electro, Finland) and expressed in ms².
Baseline to 6 weeks.
Change from baseline in high-frequency power at 6 weeks
Time Frame: Baseline to 6 weeks.
high-frequency power High-frequency component measured with Polar V800 (Polar Electro, Finland), expressed in ms².
Baseline to 6 weeks.
Change from baseline in Low-frequency to high-frequency ratio at 6 weeks
Time Frame: Baseline to 6 weeks.
Low-frequency to high-frequency ratio measured with Polar V800 (Polar Electro, Finland).
Baseline to 6 weeks.
Change from baseline in Timed Up and Go Time at 6 weeks
Time Frame: Baseline and 6 weeks.
time in seconds to stand from a chair, walk 3 meters, turn, return, and sit down.
Baseline and 6 weeks.
Change from baseline in 30-second Chair stand repetitions at 6 weeks
Time Frame: Baseline and 6 weeks.
number of full stands from a seated position completed in 30seconds.
Baseline and 6 weeks.
Change from baseline in handgrip strength at 6 weeks
Time Frame: Baseline and 6 weeks.
maximum voluntary isometric handgrip strength measured using handheld dynamometer instrutherm DM-90 (Brazil), expressed in kilogram-force (kgf).
Baseline and 6 weeks.
Change from baseline in isometric knee extensor strength at 6 weeks
Time Frame: Baseline and 6 weeks.
Maximum isometric knee extensor strength measured at 90º knee angle using horizontal leg press, expressed in kilogram-force (kgf).
Baseline and 6 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Raphael Mendes Ritti Dias

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Raphael M Ritti-Dias, PhD, University of Nove de Julho

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 30, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 16, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 26, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 4, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 1, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 27, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • DYNISO-HT

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data will be anonymized and shared after the completion of the study and publication of the main results

IPD Sharing Time Frame

Data will be shared adter the publication of the main trial

IPD Sharing Access Criteria

Will be avaliable in open repositories

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings